Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alvotech And Jamp Launch First Stelara Biosimilar In Canada

Jamteki Version Of Ustekinumab Introduced By Jamp Is Country’s First Stelara Rival

Executive Summary

Alvotech and Jamp have launched Canada’s first Stelara biosimilar, just a couple of weeks after Alvotech disclosed a settlement that would allow its ustekinumab product to be introduced in markets around the world.

You may also be interested in...

Alvotech Sees Opportunities Open Up With US Approvals

With long-awaited US approvals now rolling in and a growing pipeline of future biosimilars, further opportunities are opening up for Alvotech – including potentially launching a second interchangeable Stelara biosimilar in the US just a few months after market formation – chief commercial officer Anil Okay and chief strategy officer Ming Li tell Generics Bulletin.

Alvotech Raises Further Funds After FDA Green Light

Alvotech has announced a share sale that will raise $166m for the biosimilars developer, in the wake of its recent US Food and Drug Administration approval for its AVT02 adalimumab biosimilar, Simlandi.

Alvotech Lines Up US Biosimilar Approvals After FDA Inspection

Alvotech has revealed details of exactly when it expects to win US FDA approvals for its Teva-partnered Humira and Stelara biosimilars, after an agency reinspection of its manufacturing plant in Reykjavik, Iceland resulted in just a single “readily addressable” Form 483 observation.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts